Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB.

Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Abstract Text:

Lawrence P Carter,Brian D Richards,Miriam Z Mintzer,Roland R Griffiths,

Although preclinical studies suggest that GHB has low likelihood for abuse, case reports indicate that GHB is abused. This study evaluated the relative abuse liability of GHB in 14 volunteers with histories of drug abuse. Psychomotor, subjective, and cognitive effects of a broad range of GHB doses (2-18 g/70 kg), up to a dose that produced severe behavioral impairment in each participant, were compared to placebo and two abused sedative/hypnotic drugs, triazolam (0.5 and 1 mg/70 kg) and pentobarbital (200 and 400 mg/70 kg), under double-blind, double-dummy conditions at a residential research facility. In general, GHB produced effects similar to triazolam and pentobarbital, although GHB was not identified as a benzodiazepine or barbiturate by participants that correctly identified triazolam and pentobarbital as such. On most measures of likelihood of abuse (eg ratings of liking, reinforcing effects), effects of pentobarbital were significantly greater than those of triazolam, with GHB being intermediate. GHB produced significantly greater negative subjective effects, including nausea, than the other drugs. Memory impairment after GHB was less than that after triazolam and pentobarbital. Within participants, the dose-effect function for sedation was steeper for GHB than for triazolam and pentobarbital. Also, at higher doses, GHB was associated with greater sedation and more variability across participants in sedation. Taken together, these data suggest that the profile of effects of GHB only partially overlaps with that of triazolam and pentobarbital. Although the likelihood for GHB to be abused is intermediate to triazolam and pentobarbital, the possibility of accidental overdose (ie greater sedation than intended) with GHB appears to be greater.

Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Publishing Authors By Initials

LP Carter,BD Richards,MZ Mintzer,RR Griffiths,

For similar heterocyclic compounds: heterocyclic compounds, 2-ring: benzazepines: benzodiazepines: triazolam research abstracts see: heterocyclic compounds: heterocyclic compounds, 2-ring: benzazepines: benzodiazepines: triazolam research

PUBMED ID PMID:

MEDLINE DATE:

Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Neuropsychopharmacology : official publication of

VOLUME: 31

Page Numbers: 2537-51

Journal Abbreviation: Neuropsychopharmacology

ISSN: 0893-133X

DAY: 26

MONTH: 07

YEAR: 2006

Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8904907

Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Keywords Mesh Terms:

KEYWORDS: Triazolam

MESH TERMS: pharmacology

Chemical & Substance for Abstract: Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Information

Substance Name: Pentobarbital

Registry Number: 76-74-4

Grant and Affiliation Information for Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB.

AFFILIATION: Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA.

Country: United States

AGENCY: United States NIDA

GRANT: R01 DA003889

ACRONYM: DA

MEDLINETA: Neuropsychopharmacology

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB Related Publications

• A survey of school nursing provision in the UK.
• A triazolam/amphetamine dose-effect interaction study: dissociation of effects on memory versus arousal.
• Attenuation of cocaine-seeking by GABA B receptor agonists baclofen and CGP44532 but not the GABA reuptake inhibitor tiagabine in baboons.
• Beware of varicose veins in a patient with sturge-weber syndrome.
• Collagenous colitis and eosinophilic gastritis in a 4-year old girl: a case report and review of the literature.
• Complications of internal fixation in paediatric fractures.
• Detection of chlamydial DNA by PCR.
• Differential effects of scopolamine and lorazepam on working memory maintenance versus manipulation processes.
• Expression of extremely low levels of thymidine kinase from an acyclovir-resistant herpes simplex virus mutant supports reactivation from latently infected mouse trigeminal ganglia.
• General surgical patients' perspectives of the adequacy and appropriateness of discharge planning to facilitate health decision-making at home.
• Global strategies to prevent herpes zoster and its associated complications.
• High frequency localised "hot spots" in temporal lobes of patients with intractable tinnitus: a quantitative electroencephalographic (QEEG) study.
• Imaging bladder sensations.
• Implementing epilepsy guidelines within a learning disability service.
• Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.
• Lymphocyte trafficking in psoriasis: a new perspective emphasizing the dermal dendrocyte with active dermal recruitment mediated via endothelial cells followed by intra-epidermal T-cell activation.
• Magnetic resonance perfusion imaging in malformations of cortical development.
• Neural representation of auditory size in the human voice and in sounds from other resonant sources.
• PTEN and NDUFB8 aberrations in cervical cancer tissue.
• Pathogenic aspects of cutaneous photoaging.
• Patient and caregiver counselling after the intensive care unit: what are the needs and how should they be met?
• Pharmacogenetics of migraine: genetic variants and their potential role in migraine therapy.
• Reaching standards for dissemination: a case study.
• Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB.
• Review article: the genetic basis of haemochromatosis.
• Seasonality in six enterically transmitted diseases and ambient temperature.
• Self-management education programmes by lay leaders for people with chronic conditions.
• Steroids for traumatic optic neuropathy.
• Time for a Change: Is it Time to Consider Job Redesign for Therapy Radiographers?
• Translation and equivalence assessment for a Japanese version of the modified Parental Nurturance Scale: a comparative study.